Drug
Nusinersen
Nusinersen: highest development phase Post-Market, developed by Biogen. 3 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Biogen
Trials
| Drug | Phase | Indication |
|---|---|---|
| Nusinersen NCT04488133 | Post-Market | Muscular Atrophy, Spinal |
| Nusinersen NCT02462759 | Phase 2 | Spinal Muscular Atrophy |
| nusinersen NCT01494701 | Phase 1 | Spinal Muscular Atrophy |
Latest
No recent events.
Follow Nusinersen on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.